Details of a Researcher - Chiyoda, Tatsuyuki

Papers - Chiyoda, Tatsuyuki

Division display 81 - 85 of about 85 ／ All the affair displays >>

Lymph node metastasis in grossly apparent stages I and II epithelial ovarian cancer

Nomura Hiroyuki, Tsuda Hiroshi, Susumu Nobuyuki, Fujii Takuma, Banno Kouji, Kataoka Fumio, Tominaga Eiichiro, Suzuki Atsushi, Chiyoda Tatsuyuki, Aoki Daisuke

International Journal of Gynecological Cancer (LIPPINCOTT WILLIAMS & WILKINS) 20 ( 3 ) 341 - 345 2010.04

ISSN 1048-891X

Objectives: Incidence of lymph node metastasis is relatively high even in early-stage epithelial ovarian cancers (EOC). Lymphadenectomy is important in the surgical treatment of EOC; however, the exact role of lymphadenectomy in the management of EOC remains unclear. In this study, we evaluated lymph node metastasis in stages I and II EOC patients. Patients and Methods: Seventy-nine patients with stage I/II EOC underwent initial surgery, and 68 patients received adjuvant platinum and taxane chemotherapy after surgery at Keio University Hospital. The patients were evaluated with respect to age at diagnosis, clinical stage, histology, histological grade, and tumor laterality. Results: Of the 79 patients, 10 (12.7%) had lymph node metastasis. Of these, 4 (5.1%) had lymph node metastasis in paraaortic lymph node (PAN) only, 1 (1.3%) in pelvic lymph node (PLN) only, and 5 (6.3%) in both PAN and PLN. The incidence of serous-type lymph node metastasis in PAN, PAN + PLN, and total was higher than nonserous type (25% vs 1.5%, P < 0.0001;25% vs 3.0%, P = 0.001; 50% vs 5.9%, P < 0.0001). However, there was no significant difference between lymph node status and T factor or histological grade. In 78% of patients (7/9), metastases in contralateral lymph nodes were present (contralateral, 2; bilateral, 5). There was no significant difference in progression-free survival between node-positive and node-negative groups (P = 0.47). Conclusions: Based on diagnostic value, the result suggests that the role of lymphadenectomy might differ by histological type, as its therapeutic effect might be unclear. A multicenter analysis is essential for confirmation.

Access to Document (DOI)

The sensitivity and specificity of a new formula to distinguish endometrioid type endometrial carcinoma from ovarian endometrial carcinoma

Nishimura Sadako, Ito Yoichi M., Tsuda Hiroshi, Ohnishi Yoshitaka, Kataoka Fumio, Nomura Hiroyuki, Chiyoda Tatsuyuki, Suzuki Atsushi, Susumu Nobuyuki, Aoki Daisuke, Hatae Masayuki

European Journal of Obstetrics Gynecology and Reproductive Biology (ELSEVIER SCIENCE BV) 148 ( 1 ) 67 - 72 2010.01

ISSN 0301-2115

Objectives: Endometrioid type adenocarcinoma sometimes occupies both endometrium and ovary and in some cases the origin cannot be determined. Study design: In this study, we established a formula to distinguish ovarian endometrioid cancer (EOC) from endometrioid type endometrial cancer (EEC), based on our previous report of cyclin and KI67 expression pattern by immunohistochemistry of 36 EECc and 37 OECc by the logistic regression. We calculated the diagnostic accuracy using 92 test samples retrospectively and finally could diagnose the origin of 16 cases in whom endometrioid type adenocarcinoma arose in both ovary and endometrium and could be determined by Scully's criteria, and 15 cases in whom endometrioid type adenocarcinoma arose in both ovary and endometrium and Scully's criteria were not usuful retrospectively. Results: The estimated formula is as follows: Logit(Prob(EOC)) = -1.1437 - 0.0853 CNA + 0.0423 CNB + 0.173 CND1 + 0.0129 CNE + 0.0224 CNF + 0.0508 KI67, where Prob(EOC) is the probability that a clinical sample is EOC. If Prob(EOC) is larger than 0.5, the diagnosis is ovarian cancer; if less than 0.5 it is endometrial cancer. Finally, using the formula, 37 of 48 EECs (77.1%) and 33 of 44 EOCs (75.0%) were correctly classified, with an accuracy of 76.1% (p < 0.0001), retrospectively. In 12 of the 16 cases (75%) who could be determined by Scully's criteria, the origin determined by Scully's criteria was concordant with the origin determined by the formula retrospectively. In the other 15 cases, 12 cases were judged as ovary/ovary, 2 cases were judged as uterus/uterus and 1 case was judged as uterus/ovary. Conclusion: The formula we established was thought to be useful to distinguish the origin of the cases in whom endometrioid type adenocarcinoma arises in both ovary and endometrium.

Access to Document (DOI)

Effects of third-line chemotherapy for women with recurrent ovarian cancer who received platinum/taxane regimens as first-line chemotherapy

Chiyoda T., Tsuda H., Nomura H., Kataoka F., Tominaga E., Suzuki A., Susumu N., Aoki D.

European Journal of Gynaecological Oncology (I R O G CANADA, INC) 31 ( 4 ) 364 - 368 2010

ISSN 0392-2936

Purpose: At present, it remains unclear whether the third-line chemotherapy has clinical benefit. In this study, we retrospectively evaluated the effect of third-line chemotherapy. Methods: We reviewed the medical records of 40 women with recurrent epithelial ovarian cancer (EOC) who received third-line chemotherapy after platinum/taxan regimens as first line chemotherapy. Results: In the first recurrence, 23 cases were platinum-sensitive and 17 cases were platinum-resistant. The cases for which the treatment-free interval from second-line chemotherapy (TFI) was ≥ 3 months had a higher non-PD rate than those with TFI < 3 months (86% vs 33%, p = 0.002). In addition, the median overall survival (OS) was longer for TFI ≥ 3 months than for TFI < 3 months (1195 days vs 235 days, p = 0.004). Finally, TFI was an independent significant prognostic factor by univariate (HR 3.28, p = 0.006) and multivariate (HR 3.21, p = 0.018) proportional hazard tests. Conclusion: TFI from second-line chemotherapy may predict a survival benefit of third-line chemotherapy.

Can ABCF2 protein expression predict the prognosis of uterine cancer?

Nishimura S., Tsuda H., Miyagi Y., Hirasawa A., Suzuki A., Kataoka F., Nomura H., Chiyoda T., Banno K., Fujii T., Susumu N., Aoki D.

British Journal of Cancer (NATURE PUBLISHING GROUP) 99 ( 10 ) 1651 - 1655 2008.11

ISSN 0007-0920

Uterine cervical and endometrial cancers are common malignant solid neoplasms for which there are no useful prognostic markers. In this study, we evaluate the relationship between ATP-binding cassette superfamily F2 (ABCF2) expression and clinical factors including clinical stage, histologic type, grade and prognosis in uterine cervical and endometrial cancer. Two hundred and sixty seven cervical and 103 endometrial cancers were studied. ATP-binding cassette superfamily F2 cytoplasmic expression was detected by immunohistochemical staining and scored as positive or negative. Among cervical cancer cases, 149 (55.8%) expressed ABCF2. The overall survival was longer in ABCF2-negative than ABCF2-positive cases (P=0.0069). Statistically significant prognostic factors for survival were ABCF2 positivity (risk ratio (rr)=1.437), old age (rr=1.550) and advanced stage (rr=2.577). ATP-binding cassette superfamily F2 positivity was an independent prognostic factor by multivariate proportional hazard test (P=0.0002). Among endometrial cancer cases, 72 (69.9%) were cytoplasmic ABCF2 positive. However, there was no significant relationship between ABCF2 expression and age, clinical stage, histologic type, histologic grade, oestrogen receptor status or prognosis. ATP-binding cassette superfamily F2 expression may be a useful prognostic marker in cervical but not endometrial cancer. The role of ABCF2 protein may differ depending on the type of cancer.

Access to Document (DOI)

Sox21 is a repressor of neuronal differentiation and is antagonized by YB-1

Ohba Hiroyuki, Chiyoda Tatsuyuki, Endo Emmy, Yano Masato, Hayakawa Yoshika, Sakaguchi Masanori, Darnell Robert B., Okano Hirotaka J., Okano Hideyuki

Neuroscience Letters (ELSEVIER SCI IRELAND LTD) 358 ( 3 ) 157 - 160 2004.04

ISSN 0304-3940

Sox21, a high-mobility group box transcription factor, is expressed throughout the immature neural stem/progenitor population in ventricular zone but not in the cortical plate in embryonic mouse brain and its expression is restricted to the subventricular zone in the adult brain. In undifferentiated PC12 cells, endogenous Sox21 expression is detected but its expression ceases during the nerve growth factor (NGF)-induced neuronal differentiation. Overexpression of Sox21 results in a substantial repression of NGF-induced neurite outgrowth in PC12 cells. Further, we biochemically identified a Sox21-associating protein, Y-box binding protein 1 which not only binds to Sox21 but also partially restores NGF-induced neurite outgrowth of PC12 cells inhibited by Sox21. These results suggest that Sox21 is a repressor of neuronal differentiation in the developing nervous system.

Access to Document (DOI)

　 Previous page - Next page 　